Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
60 participants
OBSERVATIONAL
2025-08-31
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
. Assess the outcome of Supraventricular tachycardia , the most effective acute and long-term management strategies and recurrence rates of SVT .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Supraventricular Tachycardias in Children
NCT07291544
Management of Supraventricular Tachycardia of Children
NCT03528616
Validity and Algorithm Development for Detection of Supraventricular Tachycardia in Children-A Clinical Pilot Study
NCT07148934
Use of Antiarrhythmic Drugs in Pediatrics
NCT04863001
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
NCT04837261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1 in 500 children. Clinical presentation varies by age. Infants may present with poor feeding, vomiting, irritability, lethargy, diaphoresis, or syncope, and may show signs of congestive heart failure if undiagnosed. Older children may report palpitations, chest discomfort, dizziness, shortness of breath, or syncope . Initial management of pediatric SVT follows the ABCDE approach (Airway, Breathing, Circulation, Disability, Exposure) to assess stability. In stable patients, treatment begins with VAGAL maneuvers, followed by ADENOSINE (0.1 mg/kg IV bolus), if needed. If adenosine fails, antiarrhythmic drugs such as β-blockers, flecainide, or amiodarone may be used. In unstable SVT, immediate synchronized cardioversion (0.5-2 J/kg) is indicated. For recurrent SVT, long-term management may include the FLEA approach: Flecainide, Lifestyle modification, Electrophysiologic study, and Ablation. Paroxysmal supraventricular tachycardias (SVTs) are considered benign if the electrocardiogram in sinus rhythm is normal, but their occurrence in children/teenagers is often associated with anxiety in parents, children and their doctors, and sometimes with embarrassing and invalidating symptoms.Invasive evaluation of tachycardia is rarely indicated for several reasons, including misdiagnosis or fear of hospitalization. Frequently, children/teenagers who complain of palpitations or tachycardia are only considered to be anxious, and for several months or years a false diagnosis of sinus tachycardia is given. It is important to provide education and counseling to patients and their families, including information about the condition, treatment options, potential complications, and psychological support. Outcomes of Supraventricular Tachycardia (SVT) in Children, Most children recover fully, either by outgrowing SVT or with curative ablation. Long-term survival is excellent, with no reduction in life expectancy in isolated SVT.. About 30-50% of infants outgrow SVT by age 1-2 . 70-85% of children do well with medications . \<5% of infants with untreated SVT may develop heart failure . \<1% are at risk of serious events like sudden death . Over 95% grow and develop normally. In this study, the outcome of SVT in pediatrics is assessed including the clinical and electrophysiological data , the most effective acute and long-term management and recurrence rates.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Not found
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of supraventricular tachycardia (SVT) based on:
* Clinical presentation
* Electrocardiogram (ECG) findings
Exclusion Criteria
* Incomplete clinical data
* Lost to follow-up during the study period
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sameh Mounir Moussa Soliman
Pediatric resident
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Hafeez Y, Quintanilla Rodriguez BS, Ahmed I, Grossman SA. Paroxysmal Supraventricular Tachycardia. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507699/
Nasir M, Sturts A, Sturts A. Common Types of Supraventricular Tachycardia: Diagnosis and Management. Am Fam Physician. 2023 Jun;107(6):631-641.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Outcome of SVT in children
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.